Document Detail

Prognostic factors in Merkel cell carcinoma: Analysis of 240 cases.
MedLine Citation:
PMID:  23200197     Owner:  NLM     Status:  Publisher    
BACKGROUND: Knowledge regarding behavior of and prognostic factors for Merkel cell carcinoma (MCC) is limited. OBJECTIVE: We sought to further understand the characteristics, behavior, prognostic factors, and optimal treatment of MCC. METHODS: A multicenter, retrospective, consecutive study of patients with known primary MCC was completed. Overall survival and survival free of locoregional recurrence were calculated and statistical analysis of characteristics and outcomes was performed. RESULTS: Among the 240 patients, the mean age at diagnosis was 70.1 years, 168 (70.0%) were male, and the majority was Caucasian. The most common location was head and neck (111, 46.3%). Immunosuppressed patients had significantly worse survival, with an overall 3-year survival of 43.4% compared with 68.1% in immunocompetent patients. In our study, patients with stage II disease had improved overall survival versus those with stage I disease, in a statistically significant manner. Patients with stage III disease had significantly worse survival compared with stage I and with stage II. Primary tumor size did not predict nodal involvement. CONCLUSION: The data presented represent one of the largest series of primary MCC in the literature and confirm that MCC of all sizes has metastatic potential, supporting sentinel lymph node biopsy for all primary MCC. Because of the unpredictable natural history of MCC, we recommend individualization of care based on the details of each patient's tumor and clinical presentation.
Tina I Tarantola; Laura A Vallow; Michele Y Halyard; Roger H Weenig; Karen E Warschaw; Travis E Grotz; James W Jakub; Randall K Roenigk; Jerry D Brewer; Amy L Weaver; Clark C Otley
Related Documents :
23973937 - Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standa...
11699397 - Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dex...
24287067 - Balancing risks and benefits of therapy for patients with favorable-risk limited-stage ...
1415307 - Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience w...
8226157 - Preoperative concomitant cisplatin/vp16 and radiotherapy in stage iii non-small cell lu...
16050567 - Advances in the management of epithelial ovarian cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-27
Journal Detail:
Title:  Journal of the American Academy of Dermatology     Volume:  -     ISSN:  1097-6787     ISO Abbreviation:  J. Am. Acad. Dermatol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-12-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7907132     Medline TA:  J Am Acad Dermatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Department of Dermatology, Mayo Clinic, Rochester, Minnesota. Electronic address:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Integrating genomic selection into dairy cattle breeding programmes: a review.
Next Document:  Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.